Cardiac Allograft Vasculopathy

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation

Early Post Transplant Cardiac Allograft Vasculopathy

Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA

Comparing PCCT With ICA and IVUS in Detecting Cardiac Allograft Vasculopathy

Unraveling Mechanism of Action of Extracorporeal Photopheresis in Heart and Lung Transplant Patients

Physiologic Assessment of Microvascular Function in Heart Transplant Patients

Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy

Microvascular Cardiac Allograft Vasculopathy Trial

Impact of SGLT2 Inhibitors in Heart Transplant Recipients

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients

Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy

Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Cardiac Mitochondrial Function After Heart Transplantation